Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment

Randall Hoover, Thomas C. Marbury, Richard A Preston, Megan Quintas, Laura E. Lawrence, Susan K. Paulson, David R. Luke, Sue K. Cammarata

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Delafloxacin is a novel anionic fluoroquinolone with robust activity against Gram-positive, Gram-negative, atypical, and anaerobic bacteria, including methicillin-resistant S aureus. Delafloxacin is currently being studied for the treatment of acute bacterial skin and skin structure infections and community-acquired pneumonia. This was a phase 1, open-label pharmacokinetic and safety study of a single intravenous dose of 300 mg delafloxacin in subjects with mild, moderate, and severe hepatic impairment (Child-Pugh class A, B, and C, respectively) compared with matched healthy controls. The effects of hepatic impairment were assessed by ANOVA of log-transformed values for AUC0-∞, Cmax, and systemic clearance, with hepatic group as a fixed effect. Mean AUC0-∞ and Cmax in each impairment group were not significantly different from those of the pooled healthy subjects (P > 0.05). The 90% confidence interval (CI) of the percentage ratios of least-squares means of AUC0-∞ did not indicate significant differences between the impairment groups and pooled healthy controls: Child-Pugh class A (mild) 114.4 (CI: 95.6, 137.0), Child-Pugh class B (moderate) 114.8 (CI: 95.9, 137.4), and Child-Pugh class C (severe) 115.1 (CI: 96.1, 137.8). A single IV infusion of delafloxacin was generally well tolerated in all treatment groups. The exposure and clearance of delafloxacin in subjects with mild, moderate, or severe hepatic impairment did not significantly differ from those of pooled, matched healthy subjects. Based on these pharmacokinetic data, dose adjustment of delafloxacin in the presence of hepatic impairment is not needed.

Original languageEnglish (US)
JournalJournal of Clinical Pharmacology
DOIs
StateAccepted/In press - 2016

Fingerprint

Clinical Pharmacology
Liver
Confidence Intervals
Healthy Volunteers
Gram-Negative Anaerobic Bacteria
Pharmacokinetics
Community-Acquired Infections
Skin
Methicillin Resistance
Fluoroquinolones
Least-Squares Analysis
ABT 492
Pneumonia
Analysis of Variance
Research Design
Safety
Therapeutics

Keywords

  • Delafloxacin
  • Fluoroquinolones
  • Hepatic impairment
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Hoover, R., Marbury, T. C., Preston, R. A., Quintas, M., Lawrence, L. E., Paulson, S. K., ... Cammarata, S. K. (Accepted/In press). Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment. Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.817

Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment. / Hoover, Randall; Marbury, Thomas C.; Preston, Richard A; Quintas, Megan; Lawrence, Laura E.; Paulson, Susan K.; Luke, David R.; Cammarata, Sue K.

In: Journal of Clinical Pharmacology, 2016.

Research output: Contribution to journalArticle

Hoover, R, Marbury, TC, Preston, RA, Quintas, M, Lawrence, LE, Paulson, SK, Luke, DR & Cammarata, SK 2016, 'Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment', Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.817
Hoover, Randall ; Marbury, Thomas C. ; Preston, Richard A ; Quintas, Megan ; Lawrence, Laura E. ; Paulson, Susan K. ; Luke, David R. ; Cammarata, Sue K. / Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment. In: Journal of Clinical Pharmacology. 2016.
@article{dee6a9f8efa9403eba1594dd712c7273,
title = "Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment",
abstract = "Delafloxacin is a novel anionic fluoroquinolone with robust activity against Gram-positive, Gram-negative, atypical, and anaerobic bacteria, including methicillin-resistant S aureus. Delafloxacin is currently being studied for the treatment of acute bacterial skin and skin structure infections and community-acquired pneumonia. This was a phase 1, open-label pharmacokinetic and safety study of a single intravenous dose of 300 mg delafloxacin in subjects with mild, moderate, and severe hepatic impairment (Child-Pugh class A, B, and C, respectively) compared with matched healthy controls. The effects of hepatic impairment were assessed by ANOVA of log-transformed values for AUC0-∞, Cmax, and systemic clearance, with hepatic group as a fixed effect. Mean AUC0-∞ and Cmax in each impairment group were not significantly different from those of the pooled healthy subjects (P > 0.05). The 90{\%} confidence interval (CI) of the percentage ratios of least-squares means of AUC0-∞ did not indicate significant differences between the impairment groups and pooled healthy controls: Child-Pugh class A (mild) 114.4 (CI: 95.6, 137.0), Child-Pugh class B (moderate) 114.8 (CI: 95.9, 137.4), and Child-Pugh class C (severe) 115.1 (CI: 96.1, 137.8). A single IV infusion of delafloxacin was generally well tolerated in all treatment groups. The exposure and clearance of delafloxacin in subjects with mild, moderate, or severe hepatic impairment did not significantly differ from those of pooled, matched healthy subjects. Based on these pharmacokinetic data, dose adjustment of delafloxacin in the presence of hepatic impairment is not needed.",
keywords = "Delafloxacin, Fluoroquinolones, Hepatic impairment, Pharmacokinetics",
author = "Randall Hoover and Marbury, {Thomas C.} and Preston, {Richard A} and Megan Quintas and Lawrence, {Laura E.} and Paulson, {Susan K.} and Luke, {David R.} and Cammarata, {Sue K.}",
year = "2016",
doi = "10.1002/jcph.817",
language = "English (US)",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment

AU - Hoover, Randall

AU - Marbury, Thomas C.

AU - Preston, Richard A

AU - Quintas, Megan

AU - Lawrence, Laura E.

AU - Paulson, Susan K.

AU - Luke, David R.

AU - Cammarata, Sue K.

PY - 2016

Y1 - 2016

N2 - Delafloxacin is a novel anionic fluoroquinolone with robust activity against Gram-positive, Gram-negative, atypical, and anaerobic bacteria, including methicillin-resistant S aureus. Delafloxacin is currently being studied for the treatment of acute bacterial skin and skin structure infections and community-acquired pneumonia. This was a phase 1, open-label pharmacokinetic and safety study of a single intravenous dose of 300 mg delafloxacin in subjects with mild, moderate, and severe hepatic impairment (Child-Pugh class A, B, and C, respectively) compared with matched healthy controls. The effects of hepatic impairment were assessed by ANOVA of log-transformed values for AUC0-∞, Cmax, and systemic clearance, with hepatic group as a fixed effect. Mean AUC0-∞ and Cmax in each impairment group were not significantly different from those of the pooled healthy subjects (P > 0.05). The 90% confidence interval (CI) of the percentage ratios of least-squares means of AUC0-∞ did not indicate significant differences between the impairment groups and pooled healthy controls: Child-Pugh class A (mild) 114.4 (CI: 95.6, 137.0), Child-Pugh class B (moderate) 114.8 (CI: 95.9, 137.4), and Child-Pugh class C (severe) 115.1 (CI: 96.1, 137.8). A single IV infusion of delafloxacin was generally well tolerated in all treatment groups. The exposure and clearance of delafloxacin in subjects with mild, moderate, or severe hepatic impairment did not significantly differ from those of pooled, matched healthy subjects. Based on these pharmacokinetic data, dose adjustment of delafloxacin in the presence of hepatic impairment is not needed.

AB - Delafloxacin is a novel anionic fluoroquinolone with robust activity against Gram-positive, Gram-negative, atypical, and anaerobic bacteria, including methicillin-resistant S aureus. Delafloxacin is currently being studied for the treatment of acute bacterial skin and skin structure infections and community-acquired pneumonia. This was a phase 1, open-label pharmacokinetic and safety study of a single intravenous dose of 300 mg delafloxacin in subjects with mild, moderate, and severe hepatic impairment (Child-Pugh class A, B, and C, respectively) compared with matched healthy controls. The effects of hepatic impairment were assessed by ANOVA of log-transformed values for AUC0-∞, Cmax, and systemic clearance, with hepatic group as a fixed effect. Mean AUC0-∞ and Cmax in each impairment group were not significantly different from those of the pooled healthy subjects (P > 0.05). The 90% confidence interval (CI) of the percentage ratios of least-squares means of AUC0-∞ did not indicate significant differences between the impairment groups and pooled healthy controls: Child-Pugh class A (mild) 114.4 (CI: 95.6, 137.0), Child-Pugh class B (moderate) 114.8 (CI: 95.9, 137.4), and Child-Pugh class C (severe) 115.1 (CI: 96.1, 137.8). A single IV infusion of delafloxacin was generally well tolerated in all treatment groups. The exposure and clearance of delafloxacin in subjects with mild, moderate, or severe hepatic impairment did not significantly differ from those of pooled, matched healthy subjects. Based on these pharmacokinetic data, dose adjustment of delafloxacin in the presence of hepatic impairment is not needed.

KW - Delafloxacin

KW - Fluoroquinolones

KW - Hepatic impairment

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84995480111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995480111&partnerID=8YFLogxK

U2 - 10.1002/jcph.817

DO - 10.1002/jcph.817

M3 - Article

C2 - 27570245

AN - SCOPUS:84995480111

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

ER -